Last reviewed · How we verify
Sofosbuvir, Ribavirin, and Stribild
Sofosbuvir, Ribavirin, and Stribild is a Direct-acting antiviral (DAA) combination; antiretroviral combination Small molecule drug developed by Saint Michael's Medical Center. It is currently FDA-approved for Chronic hepatitis C virus infection (genotypes 1-6), Hepatitis C virus infection in HIV co-infected patients.
This combination targets hepatitis C virus (HCV) through multiple mechanisms: sofosbuvir inhibits viral RNA polymerase, ribavirin is a nucleoside analog that disrupts viral replication, and Stribild (elvitegravir/cobicistat/tenofovir/emtricitabine) is an antiretroviral combination for HIV co-infection.
This combination targets hepatitis C virus (HCV) through multiple mechanisms: sofosbuvir inhibits viral RNA polymerase, ribavirin is a nucleoside analog that disrupts viral replication, and Stribild (elvitegravir/cobicistat/tenofovir/emtricitabine) is an antiretroviral combination for HIV co-infection. Used for Chronic hepatitis C virus infection (genotypes 1-6), Hepatitis C virus infection in HIV co-infected patients.
At a glance
| Generic name | Sofosbuvir, Ribavirin, and Stribild |
|---|---|
| Sponsor | Saint Michael's Medical Center |
| Drug class | Direct-acting antiviral (DAA) combination; antiretroviral combination |
| Target | HCV NS5B RNA polymerase; HIV integrase; HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Virology/Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Sofosbuvir is a nucleotide analog inhibitor of the HCV NS5B RNA-dependent RNA polymerase, directly blocking viral replication. Ribavirin is a broad-spectrum antiviral nucleoside analog that enhances immune response and inhibits viral polymerase. Stribild is an HIV integrase inhibitor combined with a pharmacokinetic booster and two nucleoside reverse transcriptase inhibitors, used when HCV/HIV co-infection is present. Together, these agents provide direct-acting antiviral therapy for HCV with concurrent antiretroviral coverage.
Approved indications
- Chronic hepatitis C virus infection (genotypes 1-6)
- Hepatitis C virus infection in HIV co-infected patients
Common side effects
- Fatigue
- Headache
- Nausea
- Anemia
- Insomnia
- Diarrhea
- Rash
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sofosbuvir, Ribavirin, and Stribild CI brief — competitive landscape report
- Sofosbuvir, Ribavirin, and Stribild updates RSS · CI watch RSS
- Saint Michael's Medical Center portfolio CI
Frequently asked questions about Sofosbuvir, Ribavirin, and Stribild
What is Sofosbuvir, Ribavirin, and Stribild?
How does Sofosbuvir, Ribavirin, and Stribild work?
What is Sofosbuvir, Ribavirin, and Stribild used for?
Who makes Sofosbuvir, Ribavirin, and Stribild?
What drug class is Sofosbuvir, Ribavirin, and Stribild in?
What development phase is Sofosbuvir, Ribavirin, and Stribild in?
What are the side effects of Sofosbuvir, Ribavirin, and Stribild?
What does Sofosbuvir, Ribavirin, and Stribild target?
Related
- Drug class: All Direct-acting antiviral (DAA) combination; antiretroviral combination drugs
- Target: All drugs targeting HCV NS5B RNA polymerase; HIV integrase; HIV reverse transcriptase
- Manufacturer: Saint Michael's Medical Center — full pipeline
- Therapeutic area: All drugs in Virology/Infectious Disease
- Indication: Drugs for Chronic hepatitis C virus infection (genotypes 1-6)
- Indication: Drugs for Hepatitis C virus infection in HIV co-infected patients
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing